Navigation Links
Attention Regado Biosciences, Inc. Investors: Regado Misled Investors According to a Recently Filed Class Action

SAN DIEGO & BASKING RIDGE, N.J., July 14, 2014 /PRNewswire/ -- Shareholder rights law firm Robbins Arroyo LLP announces that an investor of Regado Biosciences, Inc. (NASDAQ: RGDO) has filed a federal securities fraud class action complaint in the U.S. District Court for the District of New Jersey.  The complaint alleges that the company and certain of its officers and directors violated the Securities Exchange Act of 1934 between August 22, 2013 and July 9, 2014 (the "Class Period").  Regado is a biopharmaceutical company that focuses on the discovery and development of antithrombotic drug systems for acute and sub-acute cardiovascular and other indications.

Regado Is Accused of Misrepresenting Revolixys™ Kit Clinical Trail

According to the complaint, shares of Regado fell multiple times, beginning with an initial decline of $3.95 per share, or over 58%, to close at $2.81 on July 3, 2014 following an announcement by the company that it was voluntarily suspending the Phase 3 trial of its Revolixys™ Kit, known as REG1, an anticoagulant intended for use in patients with a wide variety of acute coronary syndromes, following a review of the Data Safety Monitoring Board to determine the safety and treatment benefit-risk ratio of the 3,234 patients enrolled in the study. Shortly thereafter, on July 9, 2014, Regado shares fell an addition $0.19 per share, or 7%, to close at $2.51 on July 10, 2014 following a subsequent announcement by the company that the U.S. Federal Drug Administration placed a hold on all patient enrollment and dosing in the Phase 3 trial of REG1. 

The complaint further alleges that Regado knew and failed to disclose that its REG1 Phase 3 trial patients were experiencing frequent and severe allergic reactions that would ultimately require the trial to be suspended.

Regado Investors Are Encouraged to Contact Shareholder Rights Law Firm Robbins Arroyo LLP

If you invested in Regado and would like to discuss your shareholder rights, please contact attorney Darnell R. Donahue at (800) 350-6003,, or via the information form on the firm's shareholder rights blog:

Robbins Arroyo LLP is a nationally recognized leader in securities litigation and shareholder rights law.  The firm represents individual and institutional investors in shareholder derivative and securities class action lawsuits, and has helped its clients realize more than $1 billion of value for themselves and the companies in which they have invested. 

Attorney Advertising. Past results do not guarantee a similar outcome.  

Darnell R. Donahue
Robbins Arroyo LLP
(619) 525-3990 or Toll Free (800) 350-6003

Logo -

SOURCE Robbins Arroyo LLP
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. Maroon 5 Lead Singer Adam Levine and Shire Announce "The Own It Project," Encouraging Adults with Attention-Deficit/Hyperactivity Disorder to Tell Their Stories Through a National Contest
2. Texas Medicaid Managed-Care Problems Gaining National Attention
3. Attention Veterans: New Medtech Job Training Program Accepting Applications through Friday, August 31
4. More than Morning Sickness: Kate Middletons Pregnancy Announcement Draws Attention to Rare Pregnancy Condition Known as Hyperemesis Gravidarum (HG)
5. GC-Rise Attracts Attention in Health Capital Market
6. Hepatitis Awareness: Bringing Attention to a Silent Epidemic
7. Attention Gates Foundation: Alsa Refinish Requests Your Help to Reduce Needle Use Worldwide
8. Regado Biosciences, Inc. to Present at the 2012 Wedbush PacGrow Life Sciences Conference in New York, NY
9. Regado Biosciences, Inc. to Present at the Canaccord Genuity 32nd Annual Growth Conference in Boston, MA
10. Regado Biosciences, Inc. to Present at the UBS Global Life Sciences Conference 2012 in New York, NY
11. Regado Biosciences, Inc. to Present at the Oppenheimer 23rd Annual Healthcare Conference in New York, NY
Post Your Comments:
(Date:11/27/2015)... 27, 2015 Ein neuer ... Krebs.   --> Ein neuer Kombinationsansatz ...   --> Ein neuer Kombinationsansatz ...   Clinical Cancer Research vom ... Cancer Research vom 6. November 2015 berichtet. ...
(Date:11/26/2015)... India , November 27, ... --> --> ... personal emergency response system (PERS) ... steadily for 5 years with ... region expected to see a ...
(Date:11/26/2015)... , Nederland, November 26, 2015 ... Een nieuwe aanpak combineert immunotherapie met ... kanker. ) ...      (Photo: ) ... Leids Universitair Medisch Centrum (LUMC) ...
Breaking Medicine Technology:
(Date:11/28/2015)... ... November 28, 2015 , ... StatRad ... has added Chris Hafey and Claude Hooton to its board of directors. The ... North America (RSNA) 2015 Annual Meeting and continues to strategically transform its focus ...
(Date:11/28/2015)... ... ... Trying to relax on a couch can actually be uncomfortable, so an ... due to personal experience with a bad back," he said. , This easy-to-use, versatile ... as increases support. It also makes it easier to eat, do other activities and ...
(Date:11/28/2015)... ... November 28, 2015 , ... Pixel Film Studios is back ... to choose from, the possibilities are endless. Users have full control over angle of ... Pulse masking effects, users are sure to get heads to turn. , ProPanel: Pulse ...
(Date:11/27/2015)... ... 27, 2015 , ... According to an article published November 13th ... in Washington D.C. revolved around the fact that proper dental care, both at-home and ... the link between periodontal disease (more commonly referred to as gum disease) and diabetes. ...
(Date:11/27/2015)... CO (PRWEB) , ... November 27, 2015 , ... According ... cities are not changing the way that they are handling security in light of ... police and security presence in an attempt to stop an attack from reaching U.S. ...
Breaking Medicine News(10 mins):